Laboratorios Farmaceuticos Rovi, S.A.
Laboratorios Farmaceuticos Rovi, S.A. (LABFF) Financial Performance & Income Statement Overview
Explore the financials of Laboratorios Farmaceuticos Rovi, S.A. (LABFF), including yearly and quarterly data on income, cash flow, and balance sheets.
Laboratorios Farmaceuticos Rovi, S.A. (LABFF) Income Statement & Financial Overview
Analyze Laboratorios Farmaceuticos Rovi, S.A.’s LABFF earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $154.89M | $434.41M | $235.28M | $178.16M |
| Cost of Revenue | $64.49M | $152.05M | $71.96M | $67.85M |
| Gross Profit | $90.40M | $282.36M | $163.31M | $110.31M |
| Gross Profit Ratio | $0.58 | $0.65 | $0.69 | $0.62 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $6.30M |
| SG&A Expenses | $35.09M | $60.17M | $33.22M | $32.57M |
| Operating Expenses | $67.38M | $159.29M | $73.19M | $73.13M |
| Total Costs & Expenses | $131.87M | $166.19M | $145.16M | $140.98M |
| Interest Income | $568000.00 | $233000.00 | $127000.00 | $97000.00 |
| Interest Expense | $629000.00 | $1.78M | $976000.00 | $328000.00 |
| Depreciation & Amortization | $7.28M | $7.43M | $7.14M | $6.82M |
| EBITDA | $30.76M | $40.20M | $97.47M | $44.28M |
| EBITDA Ratio | $0.20 | $0.09 | $0.41 | $0.25 |
| Operating Income | $23.02M | $123.07M | $90.12M | $37.18M |
| Operating Income Ratio | $0.15 | $0.28 | $0.38 | $0.21 |
| Other Income/Expenses (Net) | -$170000.00 | -$1.52M | -$765000.00 | -$48000.00 |
| Income Before Tax | $22.85M | $121.55M | $89.36M | $37.13M |
| Income Before Tax Ratio | $0.15 | $0.28 | $0.38 | $0.21 |
| Income Tax Expense | $4.77M | $29.01M | $20.21M | $7.75M |
| Net Income | $18.10M | $92.54M | $69.15M | $29.38M |
| Net Income Ratio | $0.12 | $0.21 | $0.29 | $0.16 |
| EPS | $0.35 | $1.81 | $1.30 | $0.55 |
| Diluted EPS | $0.35 | $1.81 | $1.30 | $0.55 |
| Weighted Avg Shares Outstanding | $51.15M | $51.12M | $53.38M | $53.38M |
| Weighted Avg Shares Outstanding (Diluted) | $51.15M | $51.12M | $53.38M | $53.38M |
Over the past four quarters, Laboratorios Farmaceuticos Rovi, S.A. demonstrated steady revenue growth, increasing from $178.16M in Q2 2024 to $154.89M in Q1 2025. Operating income reached $23.02M in Q1 2025, maintaining a consistent 15% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $30.76M, reflecting operational efficiency. Net income dropped to $18.10M, with EPS at $0.35. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan